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ttp://dx.doi.org/10.1016/j.jmoldx.2013.11.006This proof-of-concept study demonstrates the application of a novel nucleic acid detection platform to
detect Clostridium difﬁcile in subjects presenting with acute diarrheal symptoms. This method ampliﬁes
three genes associated with C. difﬁcile infection, including genes and deletions (cdtB and tcdC) associated
with hypervirulence attributed to the NAP1/027/BI strain. Ampliﬁcation of DNA from the tcdB, tcdC, and
cdtB genes was performed using a droplet-based sandwich platform with quantitative real-time PCR in
microliter droplets to detect and identify the ampliﬁed fragments of DNA. The device and identiﬁcation
system are simple in design and can be integrated as a point-of-care test to help rapidly detect and
identify C. difﬁcile strains that pose signiﬁcant health threats in hospitals and other health-care com-
munities. (J Mol Diagn 2014, 16: 244e252; http://dx.doi.org/10.1016/j.jmoldx.2013.11.006)Supported by the National Science Foundation (CBET 0653835 to A.T.),
NIH grant 1R21 A1073808-01 A1 (A.T.), and the Rhode Island Space
Grant NASA Graduate Fellowship (S.L.A.).
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School of Medicine, New Haven, CT.Clostridium difﬁcile is an anaerobic, spore-forming, Gram-
positive bacterium that colonizes the human colon and
typically presents as an opportunistic infection after other
colonic ﬂora have been eradicated by commonly used
antibiotics.1e3 C. difﬁcile infection can cause severe diar-
rhea, pseudomembranous colitis, and toxic megacolon, and
may require urgent colectomy or result in death.1e5 C.
difﬁcile infection has rapidly increased in incidence,
severity, and mortality, particularly in the United States,
Canada, and Europe, and C. difﬁcile is the leading cause of
nosocomial infectious mortality.4e7 In the United States, C.
difﬁcile infection was responsible for $4.8 billion in excess
hospital costs in 2008 and an estimated 14,000 deaths from
2006 to 2007.8,9 The changing epidemiology of C. difﬁcile
has been marked by hospital outbreaks due to a hypervirulent
strain, NAP1/027/BI, characterized by severe disease and
increased morbidity and mortality.10e13 With the emergencestigative Pathology
.of the NAP1/027/BI strain, there is a critical need for a highly
sensitive and rapid method of detection and strain typing in
health-care settings.4,14
Current methods of diagnosing C. difﬁcile include stool
culture, toxin testing, enzyme immunoassays, and PCR.
Although stool culture and cytotoxicity tests provide high
sensitivity and speciﬁcity, these methods are impractical in
most clinical settings, because they require 2 to 3 days to
complete, during which time clinicians must rely on
Assay for C. difﬁcile Virulence Genesempirical treatment of disease with antibiotics.3,15,16 Com-
mercial enzyme immunoassay kits for C. difﬁcile toxins A
and B are highly speciﬁc and rapid, but often lack sensi-
tivity, which can be as low as 65%.16e20 Several multiplex
PCR assays have been reported to identify various genes
associated with C. difﬁcile, including two commercially
available tests, one of which has the ability to differentiate
between the NAP1/027/BI strain and other toxigenic strains
of C. difﬁcile.15,21e26
Here, we describe a novel PCR assay coupled with a small-
volume, real-time platform allowing for simple and rapid
detection of three C. difﬁcile genes: tcdB, cdtB, and tcdC; the
last is included for detection of the hypervirulent NAP1/027/
BI variant. These genes code, respectively, for toxin B, binary
toxin, and the TcdC protein suspected to regulate toxin pro-
duction.27,28 These genes were selected as targets for our assay
based on the roles these toxins and proteins play in conferring a
virulent or hypervirulent phenotype. Our assay has the ability
to indicate the presence of markers of both PCR ribotype 027
and 078 hypervirulent strains for future point-of-care testing.
This proof-of-concept study demonstrates a simple quantita-
tive real-time PCR (qPCR) platform as a potential tool for cost-
effective and timely clinical decision making.
Materials and Methods
Primer Design and Evaluation
The pathogenicity locus in the C. difﬁcile genome contains
two genes coding the toxins A (tcdA) and B (tcdB), as well
as three accessory genes (tcdC, tcdD, and tcdE ). The tcdC
gene is a putative negative regulator of tcdA and tcdB gene
expression.27,29 Some strains also produce a third toxin,
known as binary toxin, encoded by the gene cdtB. The tcdA
and tcdB genes are typically used as markers for theTable 1 Strain Information for Alignment of C. difﬁcile Sequences
Strain Year Country
630y 1982 Switzerland
CF5 1995 Belgium
M68 2006 Ireland
M120 2007 UK
BI-9 2001 USA
CD196 1985 France
BI-1 1988 USA
R20291 2006 UK
QCD-37x79 2005 Canada
QCD-76w55 1988 USA
QCD-97b34 2004 Canada
K744 2004e2006 Canada
AE70 2004e2006 Canada
AE16 2004e2006 Canada
AE978 2004e2006 Canada
CD98 2004e2006 Canada
*Accessed from GenBank (http://www.ncbi.nlm.nih.gov/genbank).
yReference strain.
ND, no data.
The Journal of Molecular Diagnostics - jmd.amjpathol.orgpresence of the organism, but other molecular markers are
required for detection of the hypervirulent NAP1/027/BI
strain or similar hypervirulent strains. Hallmarks of the
NAP1/027/BI strain include increased production of toxins
A and toxin B, as well as production of binary toxin. The
strain also carries an 18-bp deletion in the tcdC gene, which
is thought to play a role in increased toxin production.30
Three target gene segments were thus targeted for the
subtyping assay, to detect not only the presence of toxigenic
C. difﬁcile but also the hypervirulent genotype. Our assay
targets the tcdB gene, which codes for toxin B; this toxin is
present in nearly all toxigenic strains and serves as ﬁrst-line
detection for the presence of the disease-causing organ-
ism.29 We also target the regulatory gene tcdC, with the
ability to detect both the 18-bp deletion in the hypervirulent
NAP1/027/BI strain and larger deletions in other strains that
are also considered to be hypervirulent (078).31 The last
target is cdtB, expressed by the NAP1/027/BI strain. The
cdtB gene does not occur in all disease-causing C. difﬁcile
strain; it codes for the binary toxin and is associated with of
hypervirulence. Full-genome C. difﬁcile gene sequences
from 15 strains were acquired from the National Center for
Biotechnology Information and were aligned to the C. difﬁ-
cile 630 reference sequence using multiPipMaker,32 a mul-
tiple alignment tool designed to handle such large-scale
sequences. The consensus sequences for three target genes
(tcdB, cdtB, and tcdC) speciﬁc to theC. difﬁcile genome were
analyzed by visual inspection and with Primer3 Plus,33 to
identify 100% conserved regions suitable for ampliﬁcation
by PCR. Information on the strains used for the alignment is
summarized in Table 1.
The region of the tcdC gene to be ampliﬁed through PCR
was designed to include the 18-bp deletion characteristic of
the genome of the hypervirulent C. difﬁcile strain NAP1/027/
BI. For each primer pair, the primers were optimized toRibotype NAP type Accession no.*
012 ND AM180355.1
017 ND FN665652
017 ND FN668375.1
078 ND FN665653.1
001 ND FN668944.1
027 NAP1 FN538970.1
027 NAP1 FN668941.1
027 NAP1 FN545816.1
ND NAP1 NZ_CM000658.1
ND NAP1a/001 NZ_CM000661.1
ND NAP1b/006 NZ_CM000657.1
078 NAP8 HQ639679
027 NAP1 HQ639675
027 NAP1 HQ639671
027 NAP1 HQ639678
078 NAP7 HQ639674
245
Table 2 PCR Primers for Ampliﬁcation of C. difﬁcile Genes tcdB, tcdC, and cdtB
Primer name Primer sequence Tm (C) at 12 mmol/L Mg
2þ Amplicon length (bp)
tcdB Fwd 50-CTGGAGAATCTATATTTGTAG-30 54.9 328
tcdB Rev 50-GCAGTTGATACTAATTCAAC-30 56.4
tcdC Fwd 50-CTCAAAAAACAGAAATAGAAAC-30 56.7 300
tcdC Rev 50-ACCTCATCACCATCTTC-30 56.8
cdtB Fwd 50-GCAGTTAAGTGGGAAGATAG-30 59.1 190
cdtB Rev 50-TCCATACCTACTCCAACAAT-30 59.6
Fwd, forward; Rev, reverse; Tm, melting temperature.
Angione et alanneal between 53C and 60C (Table 2). The self-
dimerization and heterodimerization energies of each of the
primer pairs were evaluated in silico, using the online folding
tool DINAMelt (http://mfold.rna.albany.edu; DINAMelt
Server, RNA Institute, SUNY Albany, Albany, NY),34 to
ensure limited formation of primer dimers. Several candidate
primer pairs for each gene were obtained from Integrated
DNA Technologies (Coralville, IA). Multiple iterations of
primer design and validation of the primers in the multiplex
PCR platform were completed, to identify the optimum
grouping of three primer pairs to use on the platform.
Clinical Sample Collection and Isolation of Clinical DNA
Double-stranded DNA was isolated from anonymized stool
samples obtained from patients at Rhode Island Hospital,
Miriam Hospital, and Newport Hospital (all in Rhode Is-
land). Approval was obtained from the Institutional Review
Board of Rhode Island Hospital/Lifespan (approval no.
211049-2), which waived the need for written or verbal
informed consent from the participants; the exemption was
granted on the basis of the research involving previously
collected diagnostic specimens from subjects who could notFigure 1 Components of the droplet sandwich platform and workﬂow. A:
compound droplet (2) surrounded by a spacer (3) and covered with a coverslip
droplet in a reaction chamber. The slide dimensions are 40 mm  40 mm, and the
generated by COMSOL Multiphysics 4.3b simulation software. The ITO-coated gla
resistive surface. D: Plot of DNA ampliﬁcation with ﬂuorescent intercalating dye
(red), and the calculated threshold (black). Fluorescence is collected in real tim
arbitrary units; Norm., normalized.
246be identiﬁed, either directly or indirectly. Anonymized stool
samples were obtained from patients whose stool specimens
had already been obtained for evaluation of suspected C.
difﬁcile during clinical care by physicians not involved with
the present study. Samples were determined as positive or
negative for C. difﬁcile with a GeneOhm Cdiff PCR kit (BD
Diagnostics, La Jolla, CA) on a LightCycler qPCR system
(Roche Diagnostics, Indianapolis, IN). Stool samples were
stored at 20C. DNA was isolated using a QIAamp stool
DNA isolation kit (Qiagen, Valencia, CA; Hilden, Ger-
many) and quantiﬁed using a NanoDrop ND-1000 spec-
trophotometer (Thermo Fisher Scientiﬁc, Waltham, MA).
Isolated DNA was stored at 20C.
PCR for C. difﬁcile Detection
Target sequences were ampliﬁed by PCR, with isolated DNA
added to a ﬁnal reaction volume of 10 mL. Unless otherwise
speciﬁed, the reaction mix contained 1 Taq polymerase
buffer (New England Biolabs, Ipswich, MA), 12.0 mmol/L
MgCl2 (Life Technologies, Carlsbad, CA), 0.1 mg/mL bovine
serum albumin, 0.2 mmol/L of each dNTP (New England
Biolabs), 0.1 U/mL Taq polymerase (New England Biolabs),Exploded view of the platform components: ITO-coated glass (1) with a
(4). B: The fully assembled platform effectively sandwiches the compound
compound droplet is approximately 2.8 mm in diameter. C: Heating proﬁle
ss resistive surface heats radially up to 95C when 15 V is applied to the
shows positive samples (blue), negative samples with no change over time
e during the extension phase of PCR, using a photomultiplier tube. AU,
jmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 2 Electrophoresis gel plot of single-gene and multiplex PCR
using C. difﬁcile reference strain 630 and the NAP1/027/BI cultured isolate
VA17. The template is indicated at the top of each lane. Lanes 1 and 4, tcdB
primer set; lanes 2 and 5, tcdC primer set; lanes 3 and 6, cdtB primer set;
lanes 7 and 8, multiplex results for the reference strain 630 and the
hypervirulent VA17 isolate, respectively.
Assay for C. difﬁcile Virulence Genes0.267mmol/L of each tcdC primer, 0.267mmol/L of each cdtB
primer, and 0.167 mmol/L of each tcdB primer. After an initial
heating step of 5 minutes at 94C, the samples were ampliﬁed
for 40 cycles of 30 seconds at 94C, 30 seconds at 65C to
53C for 30 seconds (decreasing 0.5C per cycle and held
constant thereafter), and 72C for 1 minute; the samples were
then held at 72C for 5 minutes for a ﬁnal extension step.
Singleplex reactions were performed with the same condi-
tions, except that 1.5 mmol/L MgCl2 was used and the
annealing temperatureswere 55C for tcdB and tcdC and 57C
for cdtB. Target sequences were ampliﬁed either using a
conventional thermal cycler (Bio-Rad Laboratories, Hercules,
CA) or on our droplet sandwich platform (2 mL reaction mix).
The product size was determined using Agilent DNA 1000
chips on an Agilent 2100 Bioanalyzer system (Agilent
Technologies, Santa Clara CA).
Droplet Sandwich Platform
Schematics of the droplet sandwich platform and the work-
ﬂow are shown in Figure 1. The platform consists of an in-
dium tin oxide (ITO)ecoated glass resistive heater, an
imaging spacer, and a coverslip to prevent evaporation dur-
ing thermal cycling.35,36 A custom-written proportional-in-
tegral-derivative controller was used to control the droplet
temperature and was manually tuned to match the cycling
conditions for the PCR protocol. The setup includes a 2-mL
droplet of PCR mix surrounded by mineral oil, which pro-
duces a disk-shaped compound droplet (Figure 1, A and B).
Temperature and ﬂuorescence signals are collected simulta-
neously using a thermocouple (type E) and a photomultiplier
tube. The ITO-coated glass surface is optically transparent,
which makes ﬂuorescence detection simple using a standard
inverted ﬂuorescence microscope and photomultiplier tube.
A typical output graph of ﬂuorescence over time is presented
in Figure 1D. Removable ﬂuorinated ethylene propylene tape
was applied to the glass surface for each experiment to pre-
vent sample carryover and contamination and to prevent
adsorption of the PCR reagents to the glass surface.36 This
method is also useful in that droplets act as individual reac-
tion vessels, which also help limit sample carryover. All
qPCR experiments were performed with SYBR Green I dye
(Life Technologies). A heating proﬁle for the ITO-coated
glass when 15 V is applied to the resistive surface was
generated by COMSOL Multiphysics 4.3b simulation soft-
ware (Burlington, MA; Stockholm, Sweden) (Figure 1C).
The temperature proﬁle shows the temperature cycling ach-
ieved using the droplet platform at the center of the radial
heating proﬁle. The platform requires low voltage (approxi-
mately 15 V) and uses a microfan for cooling. The average
cycle time is approximately 100 seconds; the ramp rate is
approximately 3.0C/second for heating and approximately
2.0C/second for cooling. An important advantage of
droplet-based PCR over traditional PCRmethodologies is the
small sample volumes, which have decreased thermal
diffusion distances and thus allow for faster heat transfer.The Journal of Molecular Diagnostics - jmd.amjpathol.orgResults
PCR Can Selectively and Sensitively Amplify Target
Genes
Each primer pair was tested individually and in conjunction
with other primer pairs. The primers were tested with a
template concentration of 5.0 ng/mL for two positive-control
samples. In both situations, all primer pairs effectively
ampliﬁed their respective targets. An electrophoresis gel
plot of DNA ampliﬁed in a PCR assay is presented in
Figure 2. DNA isolated from cultured C. difﬁcile reference
strain 630 (C. difﬁcile ATCC BAA-1382) was used, or
DNA isolated from the C. difﬁcile strain VA17 (provided by
Dr. Curtis Donskey). The VA17 strain is designated by
pulsed-ﬁeld gel electrophoresis as the North American
Proﬁle 1 (NAP1), by PCR as ribotype 027, and by restric-
tion endonuclease analysis as type BI and is thus known as
the NAP1/027/BI strain.
In lanes 1, 2, 3, and 7 (Figure 2), reference strain 630 was
used as a template and in lanes 4, 5, 6, and 8 the NAP1/027/BI
strain was used. Lanes 1 and 4 show ampliﬁcation of a region
within the tcdB gene, which is identical for both templates, at
328 bp. In lanes 2 and 5, cdtB primer pairs were used that show
ampliﬁcation of the binary toxin gene for the NAP1/027/BI
strain, at 190 bp, but not for the reference strain 630 (because
this binary toxin gene is not present in the reference genome
and similar strains). Lanes 3 and 6 show ampliﬁcation of the
tcdC gene for both strains; however, the 18-bp deletion in the
tcdC gene for the NAP1/027/BI strain is apparent in the
downward shift of the band. The sizing results from the
Agilent Bioanalyzer system indicate an amplicon size of 300
bp for theC. difﬁcile reference strain 630 and of 282 bp for the
VA17 strain, a difference of 18 bp. These ﬁndings corroborate
that our primer set can detect the mutation in the tcdC gene
associated with virulence in NAP1/027/BI C. difﬁcile247
Table 3 Summary of Virulence Genes Detected in Clinical
Isolates of C. difﬁcile
Samples
tcdB
(BD PCR)* tcdB tcdC
tcdC 18-bp
deletion
tcdC 39-bp
deletion cdtB
Positive
(n Z 20)
20 20 11 7 2 9
Negative
(n Z 12)
0 0 0 0 0 0
*GeneOhm Cdiff PCR kit (BD Diagnostics).
Figure 3 A: Electrophoresis gel plot of multiplex PCR. A different
clinical stool DNA isolate was used as template for each ampliﬁcation, from
eight positive samples and two negative controls. A sample identiﬁer for the
template is indicated at the top of each lane. Each positive sample (lanes
1 to 8; samples AeC, EeG, L, and M) shows the 328-bp amplicon for tcdB,
followed by either a 300-bp amplicon for tcdC (lanes 1, 3, 7, and 8; samples
A, C, L, and M) or a 282-bp amplicon for tcdC with the NAP1/027/BI deletion
(lanes 2, 5, and 6; samples B, F, and G). Sample E (lane 4) shows a greater
deletion in tcdC at 261 bp. Samples with any deletion in tcdC were also
positive for binary toxin, indicated by the amplicon at 190 bp for cdtB (B, E,
F, and G). Lanes 9 and 10 (samples N and O) show representative samples of
clinical negative controls. B: Electropherogram for samples E, F, and L. The
electropherogram image shows the peaks of the three amplicons cdtB, tcdC,
and tcdB for samples E, F, and L, respectively. The base-pair shifts in the
tcdC amplicon are easily visible between 70.0 seconds and 77.5 seconds;
sample L shows the longest amplicon at 75.25 seconds, followed by sample
F (18-bp deletion) at 73.55 seconds and then sample E (39-bp deletion)
at 71.25 seconds. The peak for tcdB appears in all three samples at
79.0 seconds and cdtB in samples E and F at 64.4 seconds.
Angione et alstrains.27,28,37 We also obtained multiplex results for the
reference genome 630 and theNAP1/027/BI strain (Figure 2).
PCR was also performed on DNA isolated from 20 PCR-
positive patient stool samples and 12 PCR-negative samples
obtained from the Rhode Island Hospital Clinical Microbi-
ology Laboratory. An electrophoresis gel plot shows ampli-
ﬁed products from the multiplex PCR assay using DNA
isolates from eight positive and two negative representative
clinical stool samples (Figure 3A). Samples B, E, F, and G
show all three amplicons, the largest corresponding to tcdB,
the intermediate size corresponding to tcdC, and the smallest
corresponding to cdtB. In samples A, C, L, and M, ampliﬁ-
cation of tcdB and tcdC is shown. Virulence genes were
detected in all of the positive patient samples and in none of
the negative samples (Table 3) and (Figure 3A).248Of the set of samples tested, we successfully ampliﬁed
tcdB and tcdC in all samples, and cdtB in 9 out of 20
(Table 3). The nine samples with the amplicon for binary
toxin also exhibited a deletion in the tcdC gene, as
demonstrated by the amplicon shift visible on the gel elec-
tropherogram (Figure 3B). Seven of these samples display
an 18-bp deletion that is typically associated with the NAP1/
027/BI strain. Additionally, two samples (one of which,
sample E, is shown in Figure 3) showed a larger shift in the
tcdC gene (a 39-bp deletion). This larger deletion is often
associated with another hypervirulent strain of C. difﬁcile,
referred to as ribotype 078. Like NAP1/027/BI strain, the
078 strain is positive for binary toxin and shows both the
18-bp deletion in tcdC that confers down-regulation of toxin
management and an additional 21-bp deletion in the same
gene.11,31 The base-pair shifts in the tcdC amplicon are easily
visible in the electropherogram as ampliﬁcation peaks
(Figure 3B). The peak for tcdB in all three samples was at
79.0 seconds, and that for cdtB in two of the samples (E and
F) was at 64.4 seconds (Figure 3B). TcdBwas detected by our
assay in all positive clinical samples and none of the negative
clinical samples. Presence of tcdB in our assay also served as
a standard positive control. As expected, samples negative
for tcdBwere additionally negative for the other two genes of
interest, tcdC and cdtB. Current diagnostic methods cannot
detect the presence of tcdC or cdtB, nor the deletions in the
tcdC gene that are markers indicative of the NAP1/027/BI
strain.
Droplet Sandwich qPCR Selectively and Sensitively
Detects Target Genes
The singleplex qPCR results using the droplet platform for
each amplicon of interest (tcdB, tcdC, and cdtB) for the C.
difﬁcile 630 genome are overlaid in Figure 4A. The CT values
(12.2 for tcdB and 12.7 for tcdC) were calculated as 10 times
the SD of the background signal, as a means of evaluating
the efﬁciency and reproducibility of the ampliﬁcation. The
subsequent size analysis shows the appropriate amplicon
lengths (328 bp for tcdB and 300 bp for tcdC), as well as the
absence of cdtB (Figure 4B). The C. difﬁcile 630 strain does
not contain the cdtB gene, and the assay was appropriately
negative for this amplicon.
The ampliﬁcation curves for each amplicon for the VA17
strain, which is of the NAP1/027/BI type, are overlaid in
Figure 5A. The CT values for tcdB, tcdC, and cdtBwere 11.8,jmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 5 A: Singleplex qPCR results for tcdB, tcdC, and cdtB ampliﬁ-
cation in the VA17 NAP1/027/BI hypervirulent strain of C. difﬁcile. The
tcdB, tcdC, and cdtB amplicons have CT values of 11.8, 15.2, and 11.3,
respectively, for a starting concentration of 1.0 ng/mL. B: The corre-
sponding electrophoresis gel plot for PCR performed on the droplet sand-
wich platform shows, the amplicons are of the appropriate size: 328 bp for
tcdB, 282 bp for tcdC, and 190 bp for cdtB. The amplicon size of tcdC in-
dicates the presence of the 18-bp deletion associated with NAP1/027/BI.
Figure 4 A: Singleplex qPCR results for tcdB, tcdC, and cdtB ampliﬁ-
cation in C. difﬁcile 630. The tcdB and tcdC amplicons have CT values of 12.2
and 12.7, respectively, for a starting concentration of 1.0 ng/mL. The cdtB
gene is not present in the C. difﬁcile 630 genome, and ampliﬁcation did not
occur. B: The corresponding electrophoresis gel plot for PCR performed on
the droplet sandwich platform shows appropriate-size amplicons for tcdB at
328 bp and tcdC at 300 bp. Ampliﬁcation of cdtB shows no product, and the
assay is negative for that gene.
Assay for C. difﬁcile Virulence Genes15.2, and 11.3, respectively. The ampliﬁcation of the cdtB
gene fragmentwas themost efﬁcient, with the lowest CT value
and the most exponential curve, likely because of the shorter
amplicon size (190 bp). Smaller amplicons tend to amplify
more efﬁciently for qPCR, because of better disassociation
and primer annealing during temperature cycling. Addition-
ally, both cdtB and tcdB amplicons appeared to amplify more
efﬁciently than tcdC for this template. The proper amplicon
lengths are presented in Figure 5B, including the 18-bp
deletion in the tcdC gene indicative of the NAP1/027/BIThe Journal of Molecular Diagnostics - jmd.amjpathol.orgstrain. Overall, the standard deviation between ampliﬁcation
of different gene fragments at 1.0 ng/mL for this template was
2.1 cycles (n Z 3 for each template). In comparing efﬁ-
ciency between the 630 genome andVA17 templates for tcdB
and tcdC, the standard deviation was 0.3 and 1.8 cycles
(n Z 3 for each gene fragment) respectively. Overall, this
variation is low, indicating that the amplicons function with
appropriate efﬁcacy at the same template concentrations,
across two different strain types, which represent the majority249
Angione et alof clinical samples typed. The larger error in ampliﬁcation of
the tcdC gene could be due to differences in the templates,
because one contains the 18-bp deletion and the other does
not. For all genes, the no-template controls showed no change
in ﬂuorescence over time and thus graphed as ﬂat lines. SYBR
Green I was used because it is a common intercalating dye to
validate the assay in real time. Melting-curve analysis could
be performed with a dye such as SYBR Green I or EvaGreen
(Biotium, Hayward, CA) to detect the 18-bp deletion in tcdC,
as well as the other gene sequences.
Discussion
C. difﬁcile colitis is a growing cause of morbidity and mor-
tality. The hypervirulent NAP1/027/BI strain has been asso-
ciated with increased severity of disease, mortality, and more
frequent relapses.38,39 A number of PCR and qPCR assays
have been developed to detect C. difﬁcile.40 However, several
of these assays require dedicated equipment and multiple
ﬂuorescence wavelength excitation and detection capabilities
to identify the genes of interest. One commercial example is
the Xpert C. difﬁcile/epi assay (Cepheid, Sunnyvale, CA),
which uses primers and probes for multiplexed detection of
tcdB, tcdC, and cdtB; it is marketed to identify the NAP1/027/
BI strain. Our assay using the droplet sandwich platform can
eliminate the need for such expensive dedicated equipment.
We have identiﬁed the presence of C. difﬁcile in clinical
stool specimens through a series of three steps: isolation of
double-stranded DNA, ampliﬁcation of segments of DNA
speciﬁc to C. difﬁcile in genes of interest that may produce
proteins conferring hypervirulence, and detection of those
PCR products through the use of qPCR or capillary elec-
trophoresis. Three sets of PCR primers were designed to
amplify three speciﬁc regions of DNA, each located within a
gene with a potential role in coding for the production of
proteins involved in the severity of illness associated with
C. difﬁcile infection.
Our assay targeted segments within the tcdB gene coding
for production of toxin B, segments within the cdtB gene
coding for production of binary toxin, and segments within
the tcdC gene with a potential role in down-regulation of
production of toxins A and B.13,41 Although the 18-bp
deletion in the tcdC gene is correlated with the NAP1/
027/BI strain, this tcdC mutation in the NAP1/027/BI strain
does not, in and of itself, lead to increased toxin produc-
tion.42 The thyX gene and other insertions in the genomes
of the 027 and 078 ribotypes have been linked to hyper-
virulence due to increased production of toxins A and
B.43,44 Although our results are consistent with several
studies linking hypervirulence to deletions in the tcdC gene,
the genetic origin of increased toxin production in these
strains has yet to be fully elucidated.27,30 Emerging infor-
mation on the genetic origin of hypervirulence will provide
additional targets for typing C. difﬁcile strains and may
prove useful in typing the 027 and 078 ribotypes and other
strains of interest.43,44250Although most current laboratory detection methods seek
to identify the tcdB gene, we have demonstrated multiplexed
ampliﬁcation and detection of tcdB, tcdC, and cdtB. Our
technique can thus be used to detect the presence of the toxin
B gene (tcdB), the binary toxin gene (cdtB), and the 18-bp
deletion in the tcdC gene that may be associated with over-
production of toxins A and B in hypervirulent C. difﬁcile
strains.13,27,28 The rapid detection of these three important
markers of infection not only indicates the presence of C.
difﬁcile, but also provides physicians with additional clini-
cally relevant data regarding infection with a hypervirulent
strain. This may help physicians to devise speciﬁc treatment
regimens and may assist in contact isolation strategies
necessary to address the challenge of C. difﬁcileeassociated
diarrhea in health-care facilities and community settings.
Our droplet-based sandwich platform maintains the sensi-
tivity and speciﬁcity required for accurate detection of genetic
markers of C. difﬁcile infection and markers associated with
the hypervirulent 027 and 078 ribotypes. A major contribu-
tion of our assay is that it detects the three genes associated
with hypervirulence, via several methodologies. The assay
can be performed as a standard PCR with detection using
electrophoresis or capillary electrophoresis or can be per-
formed as a real-time assay. Real-time multiplexing can be
achieved by using melting-curve analysis with an inter-
calating ﬂuorescent dye such as SYBR Green I or EvaGreen
or, alternatively, with sequence-speciﬁc probes such as mo-
lecular beacons or TaqMan probes as desired by the user.
Our results demonstrate a clinically relevant method for
amplifying and detecting DNA from clinical samples, thus
signiﬁcantly aiding the diagnosis of C. difﬁcile infection. Our
technique of multiplex gene ampliﬁcation provides a unique
method that is both sensitive and speciﬁc for rapidly detect-
ing C. difﬁcile in patient stool samples. This method can be
adapted to point-of-care testing and thus can assist physicians
in developing and implementing better treatment regimens
for the care of patients withC. difﬁcile infections, particularly
those with the NAP1/027/BI strain.
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